{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 50,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "other",
  "function": "cite_precedent",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide uses a visual metaphor of two antibodies merging into a single complex to represent combination therapy.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/10",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.32,
        "x": 0.64,
        "y": 0.25
      },
      "kind": "chart",
      "text": "CLINICAL PRECEDENT JNJ VEGA Ph2a study",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "094cfd59-081d-4ba2-bddb-46ec1d8877cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Rational therapeutic combinations",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b4365d9-4f0a-4dc2-bdef-4144927aa3ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: JNJ VEGA ECCO'22 Presentation",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe122258-81a3-471a-8d24-4f5ce5dc8447",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Spyre is rapidly developing combination products given clinical evidence of substantial efficacy enhancement",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72cc8c32-6416-4b90-a0a1-3a5f499dd6b3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "a430efdf-3297-456d-a6ef-0386fb3fb8b2",
      "evidence": "Citing JNJ VEGA study as clinical precedent",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 9,
      "beatId": "7c8ec290-25a9-4de4-a40c-92ef8949c4a2",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 9-12 present Spyre's strategy and pipeline.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0317e287-091e-44c2-9f1e-4137f5bb7b9e",
      "evidence": "Slides 9-12 present Spyre's strategy and pipeline, answering the question of how to address unmet needs in IBD.",
      "position": 0,
      "objective": "What problem does Spyre aim to solve and how?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}